ArticleJournal of cancer research and clinical oncology2015
BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation.
Article in Journal of cancer research and clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 42 citations in OpenAlex.
- New players in the landscape of renal cell carcinoma bone metastasis and therapeutic opportunities.International journal of cancer · 2025Review
- NKX3.1 Expression Contributes to Epithelial-Mesenchymal Transition of Prostate Cancer Cells.ACS omega · 2023Article
- Cancer Stem Cells in Renal Cell Carcinoma: Origins and Biomarkers.International journal of molecular sciences · 2023Review
- Epigenetic Silencing of BMP6 by the SIN3A-HDAC1/2 Repressor Complex Drives Melanoma Metastasis via FAM83G/PAWS1.Molecular cancer research : MCR · 2022Article
- Understanding the link between kidney stones and cancers of the upper urinary tract and bladder.American journal of clinical and experimental urology · 2022Review
- Bone Morphogenetic Protein Signaling in Cancer; Some Topics in the Recent 10 Years.Frontiers in cell and developmental biology · 2022Review
- Cancer Stem Cell for Tumor Therapy.Cancers · 2021Review
- Identification of a Novel Stem Cell Subtype for Clear Cell Renal Cell Carcinoma Based on Stem Cell Gene Profiling.Frontiers in oncology · 2021Article
- ANLN Enhances Triple-Negative Breast Cancer Stemness Through TWIST1 and BMP2 and Promotes its Spheroid Growth.Frontiers in molecular biosciences · 2021Article
- Overexpression of BMP1 reflects poor prognosis in clear cell renal cell carcinoma.Cancer gene therapy · 2020Article
- Renal carcinoma CD105-/CD44- cells display stem-like properties in vitro and form aggressive tumors in vivo.Scientific reports · 2020Article
- A Case of Heterotopic Ossification in Papillary Renal Cell Carcinoma Type 2.Case reports in urology · 2020Article
- Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities.Nature reviews. Urology · 2019Review
- Type II papillary renal cell carcinoma with heterotrophic ossification: a case report.Annals of the Royal College of Surgeons of England · 2018Article
- How BMP-2 induces EMT and breast cancer stemness through Rb and CD44?Cell death & disease · 2018Article
- BMP-2 inhibits lung metastasis of osteosarcoma: an early investigation using an orthotopic model.OncoTargets and therapy · 2018Article
- Bone mesenchymal stem cells co-expressing VEGF and BMP-6 genes to combat avascular necrosis of the femoral head.Experimental and therapeutic medicine · 2018Article
- Article
- BMP-2 induces EMT and breast cancer stemness through Rb and CD44.Cell death discovery · 2017Article
- Choosing the right cell line for renal cell cancer research.Molecular cancer · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
purposeWe have previously shown that BMP-2 induces bone formation and inhibits tumorigenicity of cancer stem cells (CSCs) in a human osteosarcoma OS99-1 cell line. In this study, we sought to determine whether BMP-2 can similarly induce bone formation and inhibit the tumorigenicity of renal CSCs identified based on aldehyde dehydrogenase (ALDH) activity in renal cell carcinoma (RCC) cell lines and primary tumors.
methodsUsing a xenograft model in which cells from human RCC cell lines ACHN, Caki-2, and primary tumors were grown in NOD/SCID mice, renal CSCs were identified as a subset of ALDH(br) cells. The ALDH(br) cells possessed a greater colony-forming efficiency, higher proliferative output, increased expression of stem cell marker genes Oct3/4A, Nanog, renal embryonic marker Pax-2, and greater tumorigenicity compared to cells with low ALDH activity (ALDH(lo) cells), generating new tumors with as few as 25 cells in mice.
resultsIn vitro, BMP-2 was found to inhibit the ALDH(br) cell growth, down-regulate the expression of embryonic stem cell markers, and up-regulate the transcription of osteogenic markers. In vivo, all animals receiving a low number of ALDH(br) cells (5 × 10(3)) from ACHN, Caki-2, and primary tumor xenografts treated with 30 µg BMP-2 per animal showed limited tumor growth with significant bone formation, while untreated cells developed large tumor masses without bone formation.
conclusionsThese results suggest that BMP-2 inhibits the tumor-initiating ability of renal CSCs and induces osseous bone formation. BMP-2 may therefore provide a beneficial strategy for human RCC treatment by targeting the CSC-enriched population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.